Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = consortium-based Public–Private Partnership

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
22 pages, 655 KB  
Article
Incentive Mechanisms in Consortium-Based PPP Projects: Considering Team Collaboration and Reciprocal Member Preferences
by Ying Sun, Zhi-Qiang Ma and Fan Yang
Buildings 2025, 15(17), 2991; https://doi.org/10.3390/buildings15172991 - 22 Aug 2025
Viewed by 755
Abstract
The incentive mechanism functions as a core safeguard to ensure the efficient execution of consortium-based Public–Private Partnership (PPP) projects and the realization of value-added outcomes. The heterogeneity of consortium members, their reciprocal preferences, and the collaborative dynamics of the team collectively contribute to [...] Read more.
The incentive mechanism functions as a core safeguard to ensure the efficient execution of consortium-based Public–Private Partnership (PPP) projects and the realization of value-added outcomes. The heterogeneity of consortium members, their reciprocal preferences, and the collaborative dynamics of the team collectively contribute to the formation of project alliances characterized by resource synergy, complementary advantages, and risk sharing. However, these same factors also contribute to the multi-layered structure of principal–agent relationships and the inherent complexity of incentive pathways and mechanisms in consortium-based PPP settings. Drawing upon the team collaboration effect and reciprocal preferences among consortium members, this study incorporated the member heterogeneity and developed three incentive models for such projects, such as the Dual-Performance (DP) mode, the Total-Performance (TP) mode, and the Individual-Performance (IP) mode. This study examined the conditions under which these incentive modes were established, the relationship between incentive intensity and optimal effort levels of consortium members, and the influence of reciprocal preferences on incentive effectiveness. Further, the selection criteria and appropriate application scenarios for each of the three incentive models were analyzed according to a comparative analysis, thereby putting forward effective suggestions for improving the effort levels of private investors in consortium-based PPP projects. The study results indicate that team synergy effects play an imperative role in improving the optimal effort levels under all three modes, whereas reciprocity preferences exhibit a negative relationship with effort in the DP and TP modes. When reciprocity remains within a moderate range, the DP mode achieves highest aggregate effort levels, whereas the IP mode induces positive incentive effects only under extreme reciprocity conditions. Thus, the application of dual incentive coefficients can enhance operational adaptability and allocative efficiency and governments should establish a multidimensional collaborative incentive for consortium-based PPP projects to strengthen effectiveness and project quality. This comprehensive evaluation provides crucial insights for policymakers, emphasizing the strategic selection of incentive mechanisms to enhance the sustainability and effectiveness of consortium-based PPP Projects. Full article
Show Figures

Figure 1

27 pages, 1051 KB  
Review
Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project
by Katharine Briggs, Montserrat Cases, David J. Heard, Manuel Pastor, François Pognan, Ferran Sanz, Christof H. Schwab, Thomas Steger-Hartmann, Andreas Sutter, David K. Watson and Jörg D. Wichard
Int. J. Mol. Sci. 2012, 13(3), 3820-3846; https://doi.org/10.3390/ijms13033820 - 21 Mar 2012
Cited by 51 | Viewed by 16585
Abstract
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical industry has generated in recent decades is not exploited as efficiently as it could be. Enhanced data availability for compound comparison (“read-across”), or for data mining to build [...] Read more.
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical industry has generated in recent decades is not exploited as efficiently as it could be. Enhanced data availability for compound comparison (“read-across”), or for data mining to build predictive tools, should lead to a more efficient drug development process and contribute to the reduction of animal use (3Rs principle). In order to achieve these goals, a consortium approach, grouping numbers of relevant partners, is required. The eTOX (“electronic toxicity”) consortium represents such a project and is a public-private partnership within the framework of the European Innovative Medicines Initiative (IMI). The project aims at the development of in silico prediction systems for organ and in vivo toxicity. The backbone of the project will be a database consisting of preclinical toxicity data for drug compounds or candidates extracted from previously unpublished, legacy reports from thirteen European and European operation-based pharmaceutical companies. The database will be enhanced by incorporation of publically available, high quality toxicology data. Seven academic institutes and five small-to-medium size enterprises (SMEs) contribute with their expertise in data gathering, database curation, data mining, chemoinformatics and predictive systems development. The outcome of the project will be a predictive system contributing to early potential hazard identification and risk assessment during the drug development process. The concept and strategy of the eTOX project is described here, together with current achievements and future deliverables. Full article
(This article belongs to the Special Issue Advances in Computational Toxicology)
Show Figures

Back to TopTop